Trial · NCT07134205
The Study of JMT101 Combined With Irinotecan as a ≥3rd-Line Treatment in Metastatic Colorectal Cancer
NCT07134205, Phase 3, Not yet recruiting, Shanghai JMT-Bio Inc.
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. The Study of JMT101 Combined With Irinotecan as a ≥3rd-Line Treatment in Metastatic Colorectal Cancer. Trials, record NCT07134205. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT07134205
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- The Study of JMT101 Combined With Irinotecan as a ≥3rd-Line Treatment in Metastatic Colorectal Cancer
- NCT number
- NCT07134205
- Status
- Not yet recruiting
- Phases
- Phase 3
- Enrollment
- 252 participants, estimated
- Lead sponsor
- Shanghai JMT-Bio Inc.
- Conditions
- Metastatic Colorectal Cancer (mCRC)
- Interventions
- JMT101, Irinotecan, Regorafenib
- First posted
- 2025-08-21
- Last updated
- 2025-08-21
Source ClinicalTrials.gov
Registered outcomes11
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Progression-free Survival (PFS) | Up to approximately 3 years | defined as the time from randomization to the first occurrence of disease progression as determined by the BIRC with use of RECIST v1.1 or death from any cause, whichever occurs first. |
| Secondary | Overall response rate (ORR) | Up to approximately 2 years | determined by the BIRC and investigator with use of RECIST v1.1 |
| Secondary | Disease Control Rate (DCR) | Up to approximately 2 years | determined by the BIRC and investigator with use of RECIST v1.1 |
| Secondary | Duration of response (DOR) | Up to approximately 2 years | determined by the BIRC and investigator with use of RECIST v1.1 |
| Secondary | Progression-free Survival (PFS) | Up to approximately 2 years | defined as the time from randomization to the first occurrence of disease progression as determined by the investigator with use of RECIST v1.1 or death from any cause, whichever occurs first. |
| Secondary | Overall Survival (OS) | Up to approximately 5 years | Duration from the date of initial treatment to the date of death due to any cause. |
| Secondary | Incidence and severity of AEs | Up to approximately 2 years | Incidence and severity of adverse events (AE). Incidence, nature, and severity of adverse events graded according to the NCI CTCAE v5.0. |
| Secondary | Serum concentration of JMT101 | Up to approximately 2 years | Serum concentration and immunogenicity of JMT101 |
| Secondary | Serum immunogenicity of JMT101 | Up to approximately 2 years | Immunogenicity of JMT101 |
| Secondary | To be assessed by European Quality of Life Five Dimensions Questionnaire (EQ-5D-5L). | Up to approximately 2 years | use EORTC QLQ-C30 questionnaire and the EQ-5D-5L questionnaire |
1 to 10 of 11Source ClinicalTrials.gov
See all 11 registered outcomesOutcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT07134205
GET https://conductscience.org/api/trials/v1/NCT07134205/registered